Prospect Capital Corporation 6.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- MD United States of America
- IPO Date
- Jun 15, 2017
- CIK
- 0001287032
- Similar Companies
- Business
- Prospect Capital Corporation 6.875% Notes due 2029 (PBC) Prospect Capital Corp - 6.875% NT REDEEM 15/06/2029 USD 25 represents senior unsecured notes issued by Prospect Capital Corporation Prospect Capital Corporation, a business development company that provides private debt and equity financing to middle-market companies across the United States; its core offerings encompass first-lien senior secured loans, second-lien loans, unitranche debt, mezzanine debt, equity investments, and structured credit strategies such as subordinated tranches of collateralized loan obligations, with a diversified portfolio spanning industries including healthcare providers, consumer finance, software, energy, manufacturing, real estate, and business services. Founded in 2004 and headquartered in New York, the company targets sponsor-backed and non-sponsor-owned businesses for refinancings, leveraged buyouts, acquisitions, recapitalizations, growth capital, and capital expenditures, maintaining a focus on income generation through interest, dividends, and capital appreciation while operating primarily in the U.S. market with investments in approximately 97 portfolio companies valued at around $6.7 billion. Recent developments include the completion of a $168 million senior unsecured note issuance due 2030, an $18 million investment in The Ridge addiction treatment facility comprising a first-lien term loan, revolver, and equity co-invested with Thesis Capital Partners, the $115 million all-cash acquisition of QC Holdings Inc. as a portfolio company, redemption of 3.706% notes due 2026, retirement of $156.2 million convertible bonds, and a tender offer for $135.7 million of additional 2026 notes, alongside portfolio rebalancing that increased first-lien debt exposure to over 70% and reduced subordinated structured notes to minimal levels.
Company News
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Safe Harbor Institutional Named Top Business Solutions Company at 2026 PBC Cannabis Banking Conference
Once Upon A Farm, PBC (OFRM) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Planet Labs PBC Q2 Earnings Call Highlights
Zevia PBC Q2 Earnings Call Highlights
Once Upon A Farm, PBC (OFRM) Q2 2026 Earnings Call Transcript
Planet Labs PBC vs. Snowflake: Is a Space Stock or AI Cloud Stock the Better Buy in 2026?
Planet Labs PBC Shareholders Back Directors, KPMG and Pay Plan at Annual Meeting
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Planet Labs PBC Q1 Earnings Call Highlights
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Planet Labs PBC Receives John Deere Sustainability Award
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men's Pre-Conception Health Complete Multivitamin Claims
Planet Labs PBC Director Sells 47K Shares Worth Over $1 Million